Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free DMAC Stock Alerts

DiaMedica Therapeutics (DMAC) Financials

DiaMedica Therapeutics logo
$7.09 +0.08 (+1.14%)
As of 01:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for DiaMedica Therapeutics

Annual Income Statements for DiaMedica Therapeutics

This table shows DiaMedica Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.26 -5.73 -11 -25 -14 -14 -19 -24 -33
Consolidated Net Income / (Loss)		 -4.26 -5.73 -11 -12 -14 -14 -19 -24 -33
Net Income / (Loss) Continuing Operations		 -4.26 -5.73 -11 -25 -14 -14 -19 -24 -33
Total Pre-Tax Income 		-4.26 -5.65 -11 -12 -14 -14 -19 -24 -33
Total Operating Income		 -4.52 -6.76 -12 -13 -14 -14 -21 -27 -34
Total Gross Profit		 0.00 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 4.52 7.26 12 25 14 14 21 27 34
Selling, General & Admin Expense		 1.31 2.74 3.69 4.49 4.88 6.16 8.16 7.62 9.78
Research & Development Expense		 3.21 4.52 7.90 8.21 8.77 7.84 13 19 25
Total Other Income / (Expense), net		 0.26 1.11 0.98 0.43 0.08 0.35 1.93 2.27 1.66
Other Income / (Expense), net		 0.26 1.11 0.98 0.43 0.08 0.35 1.93 2.27 1.66
Income Tax Expense		 0.00 0.08 0.03 0.03 0.03 0.03 0.04 0.03 0.03
Basic Earnings per Share		 ($0.72) ($0.74) ($0.89) ($0.78) ($0.65) ($0.52) ($0.60) ($0.60) ($0.70)
Weighted Average Basic Shares Outstanding		 5.94M 7.74M 11.99M 15.68M 20.77M 26.44M 32.57M 40.40M 46.98M
Weighted Average Diluted Shares Outstanding		 5.94M 7.74M 11.99M 15.68M 20.77M 26.46M 37.96M 42.86M 53.88M
Weighted Average Basic & Diluted Shares Outstanding		 5.94M 7.74M 11.99M 15.68M 20.77M 26.46M 37.96M 42.86M 53.88M

Quarterly Income Statements for DiaMedica Therapeutics

This table shows DiaMedica Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.54 -5.11 -5.20 -5.13 -6.14 -7.98 -7.73 -7.72 -8.56 -8.77 -10
Consolidated Net Income / (Loss)		 -4.47 -5.16 -5.15 -5.12 -6.27 -7.90 -7.71 -7.70 -8.62 -8.74 -10
Net Income / (Loss) Continuing Operations		 -4.47 -5.16 -5.15 -5.12 -6.27 -7.90 -7.71 -7.70 -8.62 -8.74 -10
Total Pre-Tax Income 		-4.46 -5.14 -5.14 -5.11 -6.27 -7.89 -7.70 -7.69 -8.61 -8.73 -10
Total Operating Income		 -5.16 -5.85 -5.74 -5.64 -6.88 -8.42 -8.14 -8.01 -9.03 -9.21 -10
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 5.16 5.85 5.74 5.64 6.88 8.42 8.14 8.01 9.03 9.21 10
Selling, General & Admin Expense		 1.89 2.17 2.07 1.71 1.90 1.95 2.49 2.19 2.60 2.51 2.50
Research & Development Expense		 3.27 3.68 3.68 3.93 4.98 6.47 5.66 5.82 6.44 6.70 7.99
Total Other Income / (Expense), net		 0.69 0.71 0.60 0.53 0.62 0.53 0.44 0.31 0.42 0.48 0.45
Other Income / (Expense), net		 0.69 0.71 0.60 0.53 0.62 0.53 0.44 0.31 0.42 0.48 0.45
Income Tax Expense		 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.06 - 0.05 0.01 -0.13 - 0.02 0.02 -0.06 - 0.08
Basic Earnings per Share		 ($0.12) ($0.12) ($0.14) ($0.13) ($0.15) ($0.18) ($0.18) ($0.18) ($0.17) ($0.17) ($0.19)
Weighted Average Basic Shares Outstanding		 37.95M 32.57M 37.96M 38.07M 42.75M 40.40M 42.84M 42.96M 49.63M 46.98M 53.79M
Weighted Average Diluted Shares Outstanding		 37.95M 37.96M 37.96M 42.75M 42.76M 42.86M 42.88M 51.69M 52.08M 53.88M 53.88M
Weighted Average Basic & Diluted Shares Outstanding		 37.95M 37.96M 37.96M 42.75M 42.76M 42.86M 42.88M 51.69M 52.08M 53.88M 53.88M

Annual Cash Flow Statements for DiaMedica Therapeutics

This table details how cash moves in and out of DiaMedica Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.38 15 -13 3.53 -2.70 0.02 -0.19 -1.52 13
Net Cash From Operating Activities		 -3.90 -5.70 -9.10 -9.19 -12 -12 -19 -22 -29
Net Cash From Continuing Operating Activities		 -3.90 -5.70 -9.10 -9.19 -12 -12 -19 -22 -29
Net Income / (Loss) Continuing Operations		 -4.26 -5.73 -11 -12 -14 -14 -19 -24 -33
Consolidated Net Income / (Loss)		 -4.26 -5.73 -11 -12 -14 -14 -19 -24 -33
Depreciation Expense		 0.00 0.02 0.02 0.02 0.02 0.03 0.03 0.04 0.04
Amortization Expense		 - 0.00 -0.07 -0.00 0.16 -0.01 -1.22 -1.34 -0.94
Non-Cash Adjustments To Reconcile Net Income		 0.40 0.66 1.21 1.90 1.62 1.57 1.75 2.16 3.93
Changes in Operating Assets and Liabilities, net		 -0.04 -0.64 0.39 1.20 -0.46 0.59 0.09 1.51 0.68
Net Cash From Investing Activities		 -0.02 -0.05 -3.91 -16 -21 12 -18 8.56 -2.19
Net Cash From Continuing Investing Activities		 -0.02 -0.05 -3.91 -16 -21 12 -18 8.56 -2.19
Purchase of Property, Plant & Equipment		 -0.02 -0.05 -0.00 -0.05 -0.02 -0.08 -0.02 -0.03 -0.04
Purchase of Investments		 - 0.00 -13 -40 -70 -46 -69 -50 -59
Sale and/or Maturity of Investments		 - 0.00 9.00 24 49 57 51 59 57
Net Cash From Financing Activities		 3.54 21 0.07 29 30 -0.01 37 12 44
Net Cash From Continuing Financing Activities		 3.54 21 0.07 29 30 -0.01 37 12 44
Repayment of Debt		 - - - -0.01 -0.01 - -0.01 -0.01 -0.01
Repurchase of Common Equity		 - - - - - - - 0.00 -0.40
Issuance of Common Equity		 2.92 21 0.00 29 30 0.00 37 12 43
Other Financing Activities, net		 0.62 0.65 0.07 0.05 0.24 -0.01 0.00 0.26 1.00
Cash Income Taxes Paid		 - 0.08 0.03 0.04 0.03 0.03 0.03 0.03 0.03

Quarterly Cash Flow Statements for DiaMedica Therapeutics

This table details how cash moves in and out of DiaMedica Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -3.61 2.31 -2.45 12 -9.93 -1.11 -0.44 1.52 -0.78 12 -11
Net Cash From Operating Activities		 -4.80 -3.81 -6.65 -4.52 -4.47 -6.43 -7.15 -7.60 -6.55 -7.77 -9.08
Net Cash From Continuing Operating Activities		 -4.80 -3.81 -6.65 -4.52 -4.47 -6.43 -7.15 -7.60 -6.55 -7.77 -9.08
Net Income / (Loss) Continuing Operations		 -4.47 -5.16 -5.15 -5.12 -6.27 -7.90 -7.71 -7.70 -8.62 -8.74 -10
Consolidated Net Income / (Loss)		 -4.47 -5.16 -5.15 -5.12 -6.27 -7.90 -7.71 -7.70 -8.62 -8.74 -10
Depreciation Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.02 0.01 0.01
Amortization Expense		 -0.42 -0.37 -0.33 -0.32 -0.37 -0.33 -0.26 -0.18 -0.25 -0.25 -0.19
Non-Cash Adjustments To Reconcile Net Income		 0.44 0.47 0.51 0.46 0.58 0.61 0.89 0.79 1.04 1.21 0.84
Changes in Operating Assets and Liabilities, net		 -0.35 1.23 -1.69 0.45 1.58 1.18 -0.08 -0.51 1.26 0.00 0.30
Net Cash From Investing Activities		 1.20 6.12 4.21 4.74 -5.59 5.21 6.62 8.96 -26 8.00 -2.11
Net Cash From Continuing Investing Activities		 1.20 6.12 4.21 4.74 -5.59 5.21 6.62 8.96 -26 8.00 -2.11
Purchase of Property, Plant & Equipment		 -0.01 -0.00 -0.01 - -0.01 -0.01 -0.01 -0.01 -0.02 -0.01 -0.01
Purchase of Investments		 -12 -4.87 -9.78 -8.26 -22 -11 -6.87 -9.50 -35 -8.05 -19
Sale and/or Maturity of Investments		 13 11 14 13 16 16 14 18 9.10 16 17
Net Cash From Financing Activities		 -0.01 -0.00 -0.00 12 0.12 0.12 0.09 0.16 32 12 0.42
Net Cash From Continuing Financing Activities		 -0.01 -0.00 -0.00 12 0.12 0.12 0.09 0.16 32 12 0.42
Repayment of Debt		 - - -0.00 -0.00 -0.00 - -0.00 -0.00 -0.00 -0.00 -0.00
Other Financing Activities, net		 -0.00 0.01 0.00 0.01 0.13 0.13 0.09 0.16 0.47 0.28 0.42
Cash Income Taxes Paid		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

Annual Balance Sheets for DiaMedica Therapeutics

This table presents DiaMedica Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.80 18 9.05 28 46 34 54 46 61
Total Current Assets		 1.49 18 8.84 28 45 34 54 45 61
Cash & Equivalents		 1.35 17 3.88 7.41 4.71 4.73 4.54 3.03 16
Short-Term Investments		 - 0.00 4.00 20 40 29 48 41 44
Accounts Receivable		 0.08 0.78 0.82 0.34 0.13 0.08 0.37 0.24 0.26
Prepaid Expenses		 0.06 0.37 0.05 0.06 0.20 0.25 0.41 0.23 0.48
Plant, Property, & Equipment, net		 0.04 0.10 0.06 0.07 0.07 0.14 0.13 0.15 0.15
Total Noncurrent Assets		 0.27 0.27 0.15 0.10 0.04 0.42 0.35 1.59 0.60
Other Noncurrent Operating Assets		 0.27 0.27 0.15 0.10 0.04 0.42 0.35 1.59 0.60
Total Liabilities & Shareholders' Equity		 1.80 18 9.05 28 46 34 54 46 61
Total Liabilities		 1.00 1.31 1.44 2.08 1.53 2.57 3.10 5.63 5.26
Total Current Liabilities		 1.00 1.30 1.32 2.03 1.52 2.17 2.79 5.39 5.13
Accounts Payable		 0.92 0.48 0.18 1.10 0.51 0.73 0.93 0.94 1.48
Accrued Expenses		 - 0.81 1.08 0.86 0.97 1.37 1.78 4.35 3.55
Other Current Liabilities		 0.08 0.01 0.06 0.07 0.05 0.07 0.08 0.10 0.11
Total Noncurrent Liabilities		 0.00 0.02 0.12 0.05 0.00 0.40 0.32 0.24 0.13
Other Noncurrent Operating Liabilities		 - 0.00 0.11 0.05 0.00 0.40 0.32 0.24 0.13
Total Equity & Noncontrolling Interests		 0.80 17 7.62 26 44 32 51 41 56
Total Preferred & Common Equity		 0.80 17 7.62 26 44 32 51 41 56
Total Common Equity		 0.80 17 7.62 26 44 32 51 41 56
Common Stock		 41 63 64 95 127 128 167 181 229
Retained Earnings		 -40 -46 -57 -69 -83 -96 -116 -140 -173
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.00 -0.00 -0.05 -0.07 0.01 0.02 0.05

Quarterly Balance Sheets for DiaMedica Therapeutics

This table presents DiaMedica Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 58 49 57 53 39 31 57 53
Total Current Assets		 48 47 55 51 37 31 56 52
Cash & Equivalents		 2.23 2.10 14 4.13 2.59 4.11 3.33 4.87
Short-Term Investments		 44 44 40 46 34 26 52 46
Accounts Receivable		 0.31 0.40 0.39 0.29 0.25 0.16 0.26 0.30
Prepaid Expenses		 1.11 0.57 0.57 0.28 0.65 0.68 0.45 0.73
Plant, Property, & Equipment, net		 0.14 0.13 0.15 0.15 0.15 0.15 0.15 0.14
Total Noncurrent Assets		 10 1.64 1.63 1.61 1.26 0.24 0.67 0.58
Other Noncurrent Operating Assets		 0.37 1.64 1.63 1.61 0.26 0.24 0.67 0.58
Total Liabilities & Shareholders' Equity		 58 49 57 53 39 31 57 53
Total Liabilities		 2.51 2.91 3.38 4.56 4.88 4.30 5.43 5.85
Total Current Liabilities		 2.17 2.62 3.09 4.30 4.67 4.12 5.27 5.75
Accounts Payable		 0.86 0.72 0.76 1.17 1.51 1.26 1.92 3.29
Accrued Expenses		 1.23 1.82 2.23 3.02 3.05 2.75 3.24 2.34
Other Current Liabilities		 0.08 0.09 0.10 0.10 0.11 0.11 0.11 0.12
Total Noncurrent Liabilities		 0.34 0.29 0.29 0.26 0.21 0.18 0.16 0.10
Other Noncurrent Operating Liabilities		 0.34 0.29 0.29 0.26 0.21 0.18 0.16 0.10
Total Equity & Noncontrolling Interests		 56 46 53 48 34 27 52 47
Total Preferred & Common Equity		 56 46 53 48 34 27 52 47
Total Common Equity		 56 46 53 48 34 27 52 47
Common Stock		 166 167 179 180 182 183 216 230
Retained Earnings		 -110 -121 -126 -132 -148 -155 -164 -183
Accumulated Other Comprehensive Income / (Loss)		 -0.13 -0.04 -0.05 0.08 0.01 -0.01 0.05 -0.03

Annual Metrics And Ratios for DiaMedica Therapeutics

This table displays calculated financial ratios and metrics derived from DiaMedica Therapeutics' official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 12,006,874.00 18,739,074.00 26,439,217.00 26,443,067.00 37,953,711.00 - 52,077,439.00
DEI Adjusted Shares Outstanding		 0.00 0.00 12,006,874.00 18,739,074.00 26,439,217.00 26,443,067.00 37,953,711.00 - 52,077,439.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.89 -1.33 -0.51 -0.52 -0.51 - -0.63
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -32.50% -89.24% -14.78% -9.23% -1.91% -50.59% -25.26% -30.79%
EBIT Growth		 0.00% -32.72% -87.80% -15.51% -10.59% -0.62% -41.69% -26.25% -34.10%
NOPAT Growth		 0.00% -49.61% -71.47% -9.54% -7.46% -2.60% -51.90% -25.46% -28.92%
Net Income Growth		 0.00% -34.60% -85.72% -15.43% -10.58% -0.62% -41.72% -26.12% -34.05%
EPS Growth		 0.00% -2.78% -20.27% 12.36% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -46.05% -59.80% -0.91% -33.39% 6.05% -62.70% -17.88% -31.65%
Free Cash Flow Firm Growth		 0.00% 0.00% -38.87% -0.05% -30.05% 7.40% -59.80% -16.04% -38.88%
Invested Capital Growth		 0.00% 139.71% -212.73% -499.19% 26.78% -53.95% -9.73% -86.56% -10.21%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -5.21% -16.00% 7.24% -5.77% -8.63% -11.79% -2.31%
EBIT Q/Q Growth		 0.00% 0.00% -5.17% -16.26% 6.57% -3.84% -7.77% -12.70% -2.63%
NOPAT Q/Q Growth		 0.00% 0.00% -5.96% -13.37% 6.97% -5.48% -9.67% -10.66% -2.36%
Net Income Q/Q Growth		 0.00% 0.00% -5.11% -16.27% 6.56% -3.83% -7.85% -12.62% -2.63%
EPS Q/Q Growth		 0.00% 0.00% 3.26% -2.63% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.38% -14.33% 1.70% 0.33% -5.92% -13.48% -4.80%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -9.11% 1.17% 1.39% -5.19% -12.21% -7.57%
Invested Capital Q/Q Growth		 0.00% 0.00% -755.17% -73.40% -2.93% -66.67% -215.81% -53.56% -2.25%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -1,127.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -1,352.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -1,130.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -1,146.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 101.41% 100.29% 100.22% 100.21% 100.21% 100.22% 100.12% 100.09%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -533.17% -64.34% -86.43% -73.10% -38.81% -36.06% -46.77% -53.27% -67.68%
Cash Return on Invested Capital (CROIC)		 0.00% -2,503.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -56.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -56.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -533.17% -64.34% -86.43% -73.10% -38.81% -36.06% -46.77% -53.27% -67.68%
Return on Equity Simple (ROE_SIMPLE)		 -533.17% -33.68% -139.81% -47.25% -30.87% -42.97% -37.96% -60.03% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.16 -4.73 -8.12 -8.89 -9.55 -9.80 -15 -19 -24
NOPAT Margin		 0.00% -946.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -81.06% -11.03% -20.54% -19.24% -11.13% -9.86% -10.40% -11.89% -16.70%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -29.16% -45.87% -42.91%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 547.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 904.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 1,452.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.26 -5.65 -11 -12 -14 -14 -19 -24 -33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.26 -5.64 -11 -12 -13 -14 -21 -26 -34
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 3.28 0.70 7.65 7.30 2.24 1.31 2.11 5.70 7.39
Price to Tangible Book Value (P/TBV)		 3.28 0.70 7.65 7.30 2.24 1.31 2.11 5.70 7.39
Price to Revenue (P/Rev)		 0.00 23.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.69 -1.02 -1.00 -1.05 -1.04 -1.04 -1.04 -1.06 -1.07
Leverage Ratio		 2.26 1.13 1.11 1.10 1.05 1.05 1.07 1.10 1.11
Compound Leverage Factor		 2.26 1.13 1.11 1.10 1.05 1.05 1.07 1.10 1.11
Debt to Total Capital		 0.00% 0.11% 0.17% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.11% 0.17% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 99.89% 99.83% 99.97% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 2.98 0.74 2.25 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 3.55 0.97 3.09 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -37.16 2.04 12.70 51.02 36.39 5.64 17.80 19.81 42.67
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 1.49 13.87 6.70 13.77 29.82 15.61 19.27 8.28 11.81
Quick Ratio		 1.43 13.58 6.60 13.73 29.69 15.49 19.12 8.23 11.72
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.51 -7.65 -7.65 -9.95 -9.21 -15 -17 -24
Operating Cash Flow to CapEx		 -17,727.27% -11,392.00% 0.00% -29,629.03% -61,260.00% -14,211.11% -78,033.33% -88,304.00% -72,655.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 1.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 7.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 313.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 313.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -0.55 0.22 -0.25 -1.49 -1.09 -1.68 -1.84 -3.43 -3.78
Invested Capital Turnover		 0.00 -2.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.77 -0.47 -1.24 0.40 -0.59 -0.16 -1.59 -0.35
Enterprise Value (EV)		 1.27 -4.87 50 163 54 8.28 55 188 355
Market Capitalization		 2.62 12 58 190 99 42 108 232 415
Book Value per Share		 $0.13 $2.20 $0.63 $1.39 $1.67 $1.20 $1.35 $0.95 $1.08
Tangible Book Value per Share		 $0.13 $2.20 $0.63 $1.39 $1.67 $1.20 $1.35 $0.95 $1.08
Total Capital		 0.80 17 7.63 26 44 32 51 41 56
Total Debt		 0.00 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1.35 -17 -7.87 -28 -45 -34 -53 -44 -60
Capital Expenditures (CapEx)		 0.02 0.05 -0.01 0.03 0.02 0.08 0.02 0.03 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.86 -0.15 -0.36 -1.61 -1.20 -1.84 -2.01 -4.93 -4.39
Debt-free Net Working Capital (DFNWC)		 0.49 17 7.52 26 44 32 51 39 55
Net Working Capital (NWC)		 0.49 17 7.52 26 44 32 51 39 55
Net Nonoperating Expense (NNE)		 1.10 1.00 2.53 3.40 4.04 3.88 4.49 5.77 8.69
Net Nonoperating Obligations (NNO)		 -1.35 -17 -7.87 -28 -45 -34 -53 -44 -60
Total Depreciation and Amortization (D&A)		 0.00 0.02 -0.05 0.02 0.19 0.01 -1.19 -1.30 -0.90
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -29.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 3,335.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 3,335.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.72) ($0.74) ($0.89) ($0.78) ($0.65) ($0.52) ($0.60) ($0.60) ($0.70)
Adjusted Weighted Average Basic Shares Outstanding		 5.94M 11.96M 14.14M 18.78M 26.44M 26.44M 32.57M 40.40M 46.98M
Adjusted Diluted Earnings per Share		 ($0.72) ($0.74) ($0.89) ($0.78) ($0.65) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 5.94M 11.96M 14.14M 18.78M 26.44M 26.46M 37.96M 42.86M 53.88M
Adjusted Basic & Diluted Earnings per Share		 ($0.72) ($0.74) ($0.89) ($0.78) ($0.65) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.94M 7.74M 11.99M 15.68M 20.77M 26.46M 37.96M 42.86M 53.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.16 -4.73 -8.12 -8.89 -9.55 -9.80 -15 -19 -24
Normalized NOPAT Margin		 0.00% -946.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -1,130.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.22%

Quarterly Metrics And Ratios for DiaMedica Therapeutics

This table displays calculated financial ratios and metrics derived from DiaMedica Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 37,949,422.00 37,953,711.00 37,958,000.00 37,963,916.00 42,747,832.00 - 42,855,660.00 42,883,465.00 51,688,913.00 52,077,439.00 53,882,506.00
DEI Adjusted Shares Outstanding		 37,949,422.00 37,953,711.00 37,958,000.00 37,963,916.00 42,747,832.00 - 42,855,660.00 42,883,465.00 51,688,913.00 52,077,439.00 53,882,506.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.12 -0.13 -0.14 -0.14 -0.14 - -0.18 -0.18 -0.17 -0.17 -0.19
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -58.08% -42.18% -0.04% -15.59% -35.70% -49.33% -45.49% -45.18% -33.57% -9.27% -28.46%
EBIT Growth		 -46.26% -37.26% 2.30% -14.36% -40.39% -53.55% -49.71% -50.49% -37.45% -10.63% -30.31%
NOPAT Growth		 -64.87% -47.19% -3.98% -18.92% -33.47% -43.96% -41.86% -42.02% -31.24% -9.43% -28.71%
Net Income Growth		 -46.16% -37.59% 2.30% -14.34% -40.33% -53.07% -49.62% -50.40% -37.39% -10.63% -30.30%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -103.18% -37.82% -30.73% 10.16% 6.82% -68.78% -7.46% -68.13% -46.53% -20.69% -27.04%
Free Cash Flow Firm Growth		 -79.91% -79.14% -119.24% -35.56% 21.47% -9.46% 54.39% 20.12% -53.46% -41.76% -164.11%
Invested Capital Growth		 42.09% -9.73% 89.77% 30.51% -283.68% -86.56% -1,915.57% -348.13% -65.52% -10.21% -21.69%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -4.05% -12.66% 0.60% 0.81% -22.15% -23.98% 3.15% 1.02% -12.39% -1.42% -13.86%
EBIT Q/Q Growth		 0.13% -15.12% -0.10% 0.62% -22.59% -25.91% 2.41% 0.10% -11.97% -1.35% -14.95%
NOPAT Q/Q Growth		 -8.77% -13.40% 1.83% 1.79% -22.08% -22.32% 3.27% 1.68% -12.81% -1.99% -13.77%
Net Income Q/Q Growth		 0.13% -15.43% 0.19% 0.62% -22.56% -25.92% 2.44% 0.10% -11.96% -1.39% -14.90%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 4.63% 20.53% -74.53% 32.08% 1.08% -43.94% -11.11% -6.28% 13.79% -18.55% -16.96%
Free Cash Flow Firm Q/Q Growth		 -29.31% 2.54% -39.54% 22.92% 25.09% -35.84% 41.85% -34.98% -43.92% -25.49% -8.33%
Invested Capital Q/Q Growth		 36.81% -215.81% 90.91% -283.23% -248.91% -53.56% 1.84% 14.80% -28.87% -2.25% -8.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.16% 100.43% 100.14% 100.14% 100.11% 100.11% 100.08% 100.08% 100.07% 100.11% 100.07%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -39.62% -46.77% -52.50% -35.18% -41.90% -53.27% -67.25% -73.41% -64.12% -67.68% -86.47%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -39.62% -46.77% -52.50% -35.18% -41.90% -53.27% -67.25% -73.41% -64.12% -67.68% -86.47%
Return on Equity Simple (ROE_SIMPLE)		 -32.31% 0.00% -41.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.61 -4.09 -4.02 -3.95 -4.82 -5.89 -5.70 -5.60 -6.32 -6.45 -7.34
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.87% -2.47% -3.01% -2.04% -2.74% -4.14% -4.79% -4.98% -4.35% -4.40% -6.10%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.02% -8.67% -7.39% -10.05% -14.47% -16.79% -20.63% -12.25% -11.49% -15.53%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.46 -5.14 -5.14 -5.11 -6.27 -7.89 -7.70 -7.69 -8.61 -8.73 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.88 -5.50 -5.47 -5.42 -6.62 -8.21 -7.95 -7.87 -8.85 -8.97 -10
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.76 2.11 2.27 2.10 3.73 5.70 4.78 6.16 6.88 7.39 7.72
Price to Tangible Book Value (P/TBV)		 1.76 2.11 2.27 2.10 3.73 5.70 4.78 6.16 6.88 7.39 7.72
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.04 -1.02 -1.01 -1.03 -1.06 -1.04 -1.04 -1.06 -1.07 -1.09
Leverage Ratio		 1.05 1.07 1.08 1.05 1.07 1.10 1.10 1.10 1.10 1.11 1.13
Compound Leverage Factor		 1.05 1.07 1.08 1.05 1.07 1.10 1.10 1.10 1.10 1.11 1.13
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 21.44 18.67 18.99 17.60 20.71 20.98 15.02 16.64 35.82 43.96 33.05
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 22.07 19.27 18.14 17.82 11.81 8.28 8.02 7.55 10.67 11.81 9.11
Quick Ratio		 21.56 19.12 17.93 17.63 11.75 8.23 7.84 7.34 10.55 11.72 8.98
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.03 -3.93 -5.48 -4.23 -3.17 -4.30 -2.50 -3.38 -4.86 -6.10 -6.61
Operating Cash Flow to CapEx		 -47,970.00% -127,066.67% -73,922.22% 0.00% -49,666.67% -91,914.29% -59,575.00% -126,633.33% -40,937.50% -129,416.67% -113,525.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.58 -1.84 -0.17 -0.64 -2.23 -3.43 -3.37 -2.87 -3.70 -3.78 -4.10
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.42 -0.16 1.47 0.28 -1.65 -1.59 -3.20 -2.23 -1.46 -0.35 -0.73
Enterprise Value (EV)		 42 55 59 58 129 188 125 137 300 355 313
Market Capitalization		 98 108 105 112 179 232 162 167 355 415 365
Book Value per Share		 $1.47 $1.35 $1.22 $1.41 $1.12 $0.95 $0.79 $0.63 $1.00 $1.08 $0.88
Tangible Book Value per Share		 $1.47 $1.35 $1.22 $1.41 $1.12 $0.95 $0.79 $0.63 $1.00 $1.08 $0.88
Total Capital		 56 51 46 53 48 41 34 27 52 56 47
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -56 -53 -47 -54 -50 -44 -37 -30 -55 -60 -51
Capital Expenditures (CapEx)		 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.75 -2.01 -1.65 -2.13 -3.73 -4.93 -3.56 -3.08 -4.36 -4.39 -4.72
Debt-free Net Working Capital (DFNWC)		 46 51 45 52 46 39 33 27 51 55 47
Net Working Capital (NWC)		 46 51 45 52 46 39 33 27 51 55 47
Net Nonoperating Expense (NNE)		 0.86 1.07 1.13 1.17 1.46 2.01 2.01 2.09 2.30 2.29 2.70
Net Nonoperating Obligations (NNO)		 -56 -53 -47 -54 -50 -44 -37 -30 -55 -60 -51
Total Depreciation and Amortization (D&A)		 -0.42 -0.36 -0.32 -0.31 -0.36 -0.32 -0.25 -0.18 -0.23 -0.24 -0.18
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.12) ($0.12) ($0.14) ($0.13) ($0.15) ($0.18) ($0.18) ($0.18) ($0.17) ($0.17) ($0.19)
Adjusted Weighted Average Basic Shares Outstanding		 37.95M 32.57M 37.96M 38.07M 42.75M 40.40M 42.84M 42.96M 49.63M 46.98M 53.79M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 37.95M 37.96M 37.96M 42.75M 42.76M 42.86M 42.88M 51.69M 52.08M 53.88M 53.88M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 37.95M 37.96M 37.96M 42.75M 42.76M 42.86M 42.88M 51.69M 52.08M 53.88M 53.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.61 -4.09 -4.02 -3.95 -4.82 -5.89 -5.70 -5.60 -6.32 -6.45 -7.34
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.22% 0.00%

Financials Breakdown Chart

Key Financial Trends

DiaMedica Therapeutics (NASDAQ: DMAC) remains in a classic clinical-stage biotech position: no product revenue yet, ongoing operating losses, and a balance sheet that is heavily dependent on its cash runway and investment portfolio. The latest quarter shows that the company still has a sizable liquidity cushion, but it is also burning cash at a meaningful pace as research and development continues.

  • Strong liquidity position: As of Q1 2026, DMAC held about $51.3 million in cash and short-term investments, which is a solid reserve for a small biotech.
  • No debt pressure: Total liabilities were only about $5.8 million, so the balance sheet does not appear levered.
  • Cash balance improved sequentially: Cash and equivalents rose to $4.9 million from $3.3 million in Q3 2025, while short-term investments remained substantial.
  • Capital raised in prior quarters helped funding: The company generated meaningful financing inflows in 2025, including large common-equity issuance in Q3 2025 and Q4 2025, strengthening the cash position.
  • Operating losses remain consistent: Q1 2026 net loss was about $10.1 million, compared with $8.7 million in Q4 2025 and $7.7 million in Q2 2025.
  • Revenue is still absent: DMAC reported $0 in revenue in every quarter shown, so results are still entirely driven by operating expenses and financing activity.
  • Other income continues to offset some losses: Interest and other income contributed $447,000 in Q1 2026, which helps somewhat but is not enough to change the overall loss profile.
  • Share count has increased: Weighted average basic shares were 53.8 million in Q1 2026, up from roughly 42.9 million in Q2 2025, suggesting dilution from capital raises.
  • Cash burn remains high: Operating cash flow was negative $9.1 million in Q1 2026, and the company used another $2.1 million in investing activities.
  • R&D spending is still heavy: Research and development expense was $8.0 million in Q1 2026, reflecting continued reliance on pipeline progress rather than commercial sales.

Over the last four quarters, the picture is fairly clear: DMAC is still pre-revenue and loss-making, but it has managed to preserve a meaningful cash runway through investments and equity financing. The biggest positive for investors is the balance sheet strength relative to liabilities. The biggest risk is that the company continues to burn cash without any product sales, which means future dilution or additional financing could still be on the table if development timelines extend.

From an investor perspective, DMAC looks like a high-risk, event-driven biotech name. The stock’s long-term upside will likely depend on clinical progress and the company’s ability to move a candidate closer to commercialization before the cash pile meaningfully declines.

07/21/26 01:58 PM ETAI Generated. May Contain Errors.

DiaMedica Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, DiaMedica Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

DiaMedica Therapeutics' net income appears to be on an upward trend, with a most recent value of -$32.77 million in 2025, rising from -$4.26 million in 2017. The previous period was -$24.44 million in 2024. View DiaMedica Therapeutics' forecast to see where analysts expect DiaMedica Therapeutics to go next.

DiaMedica Therapeutics' total operating income in 2025 was -$34.40 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $34.40 million

Over the last 8 years, DiaMedica Therapeutics' total revenue changed from $0.00 in 2017 to $0.00 in 2025, a change of 0.0%.

DiaMedica Therapeutics' total liabilities were at $5.26 million at the end of 2025, a 6.5% decrease from 2024, and a 424.4% increase since 2017.

In the past 8 years, DiaMedica Therapeutics' cash and equivalents has ranged from $1.35 million in 2017 to $16.82 million in 2018, and is currently $15.65 million as of their latest financial filing in 2025.

Over the last 8 years, DiaMedica Therapeutics' book value per share changed from 0.13 in 2017 to 1.08 in 2025, a change of 700.5%.


Related Companies

Financial statements for NASDAQ:DMAC last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel